miR-1-3p correlates with left ventricular function in HCM, differentiates it from DCM, and targets Clcn3, highlighting its potential as a therapeutic target.
miR-1-3p may inform HCM biomarker development; leaves open therapeutic translation from animal models.
Our data demonstrated that different cardiomyopathies had unique miRNA expression pattern. And the expression levels of miR-1-3p and miR-27a had disease-specificity and sensitivity in HCM, whereas only miR-1-3p was significantly associated with left ventricular function in HCM identifying it as a potential target to improve the cardiac function in end-stage HCM. We also provide Clcn3 as a direct target of miR-1-3p which sheds light on the mechanism of HCM.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: